Barclays PLC Buys 42,185 Shares of ALX Oncology Holdings Inc. (NASDAQ:ALXO)

Barclays PLC increased its stake in ALX Oncology Holdings Inc. (NASDAQ:ALXO) by 243.6% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 59,502 shares of the company’s stock after purchasing an additional 42,185 shares during the quarter. Barclays PLC owned approximately 0.11% of ALX Oncology worth $107,000 at the end of the most recent quarter.

A number of other hedge funds also recently modified their holdings of the stock. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in shares of ALX Oncology by 394.8% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,517 shares of the company’s stock worth $39,000 after purchasing an additional 5,200 shares during the period. Rhumbline Advisers raised its holdings in shares of ALX Oncology by 10.8% in the 2nd quarter. Rhumbline Advisers now owns 55,220 shares of the company’s stock worth $333,000 after purchasing an additional 5,360 shares during the period. AQR Capital Management LLC raised its holdings in shares of ALX Oncology by 50.7% in the 2nd quarter. AQR Capital Management LLC now owns 18,079 shares of the company’s stock worth $109,000 after purchasing an additional 6,080 shares during the period. SG Americas Securities LLC raised its holdings in shares of ALX Oncology by 33.6% in the 3rd quarter. SG Americas Securities LLC now owns 27,394 shares of the company’s stock worth $50,000 after purchasing an additional 6,888 shares during the period. Finally, Hsbc Holdings PLC bought a new stake in shares of ALX Oncology in the 2nd quarter worth approximately $63,000. Institutional investors own 97.97% of the company’s stock.

Insider Activity

In other news, Director Rekha Hemrajani purchased 30,000 shares of ALX Oncology stock in a transaction dated Monday, December 2nd. The stock was purchased at an average cost of $1.55 per share, for a total transaction of $46,500.00. Following the transaction, the director now directly owns 33,000 shares of the company’s stock, valued at approximately $51,150. This trade represents a 1,000.00 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders sold 14,443 shares of company stock worth $23,309 in the last three months. Corporate insiders own 33.40% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have issued reports on ALXO shares. Jefferies Financial Group cut shares of ALX Oncology from a “buy” rating to a “hold” rating and lowered their target price for the company from $12.00 to $2.00 in a report on Thursday, December 19th. Cantor Fitzgerald reissued an “overweight” rating on shares of ALX Oncology in a report on Wednesday, December 18th. Finally, HC Wainwright reissued a “buy” rating and set a $25.00 target price on shares of ALX Oncology in a report on Wednesday, December 18th. Three analysts have rated the stock with a hold rating and three have given a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $8.50.

ALX Oncology Stock Down 0.5 %

ALXO opened at $1.85 on Thursday. The company has a fifty day moving average price of $1.56 and a 200-day moving average price of $2.72. The firm has a market capitalization of $97.57 million, a P/E ratio of -0.62 and a beta of 0.98. The company has a debt-to-equity ratio of 0.07, a current ratio of 4.82 and a quick ratio of 4.82. ALX Oncology Holdings Inc. has a one year low of $1.19 and a one year high of $17.83.

ALX Oncology Profile

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.